ClinicalTrials.gg
CompletedNCT02281552Updated Oct 12, 2018Results posted

A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis

A Phase 3 interventional study of Tofacitinib and Tofacitinib in Rheumatoid Arthritis, sponsored by Pfizer. Completed at 36 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-10-12.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
209
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tofacitinib in Arthritis, Rheumatoid — 9 open to participants now, 9 under way, 1 of them phase 3. tofacitinib · Arthritis, Rheumatoid.

Enrollment
21st of 43
209 · median 170
Started
2014
with 2 others
Phase 3
11 of 43
1 open now
Registered
25th of 43
by date
Lead sponsor
25 of 43
Pfizer

Among the 43 studies testing tofacitinib in Arthritis, Rheumatoid, this one is the 21st largest by enrollment, is one of 3 that started in 2014, is one of 11 in phase 3, and was the 25th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

9 of the 43 studies testing tofacitinib in Arthritis, Rheumatoid are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tofacitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This is a 12 week study that will evaluate the efficacy and safety of the 11 mg tofacitinib modified release tablet taken once a day in patients with rheumatoid arthritis who continue taking methotrexate. Results for the modified release tablets will be compared to the efficacy and safety of the 5 mg tofacitinib immediate release tablets taken twice a day in patients with rheumatoid arthritis who continue taking methotrexate.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Tofacitinib, CP-690,550, Janis kinase, JAK inhibitor, modified release, Xeljanz
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of rheumatoid arthritis
  • currently taking a stable dose of methotrexate
  • no evidence of active or latent or inadequately treated tuberculosis

Exclusion criteria

Exclusion Criteria:

  • evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic or allergic disease
  • clinically significant infections within the past 6 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
209 participants (actual)

Study arms

  • Experimental
    tofacitinib modified release tablet

    Drug: Tofacitinib

  • Active comparator
    tofacitinib immediate release tablet

    Drug: Tofacitinib

Interventions

  • tofacitinib modified release 11 mg tablet administered once time a day for 12 weeks

  • tofacitinib immediate release 5 mg tablet administered twice a day for 12 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Disease Activity Score in 28 Joints Using 4 Variables (DAS28-4) (C-Reactive Protein [CRP]) at Week 12

    DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP) was calculated from swollen joint count (SJC) and tender/painful joint count (TJC) using 28 joints count, CRP (milligrams per liter \[mg/L\]) and patient global assessment of disease activity on a 100 millimeter (mm) visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (CRP) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (CRP) \[less than or equal to\] \<= 3.2 implied low disease activity and greater than (\>) 3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (CRP) less than (\<) 2.6 implied remission.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change From Baseline in Disease Activity Score in 28 Joints Using 4 Variables (DAS28-4) (Erythrocyte Sedimentation Rate [ESR]) at Week 12

    DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (millimeters per hour \[mm/hr\]) and patient global assessment of disease activity on a 100 mm visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (ESR) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (ESR) \<=3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (ESR) \<2.6 implied remission.

    Time frame: Baseline, Week 12

  2. Number of Participants Achieving an American College of Rheumatology 20 Percent [%] (ACR20) Response at Week 12

    Participants with 20% improvement in 68-tender and 66-swollen joint counts and 20% improvement in at least 3 of the 5 measures: patient's global assessment of arthritis, physician global assessment of arthritis, patient's assessment of arthritis pain, health assessment questionnaire-disability index(HAQ-DI) and CRP. Patient's global assessment of arthritis: participant assessed arthritis by 100 mm VAS, score: 0 mm (no arthritis) to 100 mm (extreme arthritis), higher score implied more arthritis. Physician global assessment of arthritis: physician judged participants arthritis by 100 mm VAS, score: 0 mm (no arthritis) to 100 mm (extreme arthritis), higher score implied more arthritis. Patient's assessment of arthritis pain: participant assessed arthritis pain by 100 mm VAS, score: 0 mm (no pain) to 100 mm (most severe pain), higher score implied more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.

    Time frame: Week 12

  3. Number of Participants Achieving an American College of Rheumatology 50% (ACR50) Response at Week 12

    Participants with 50% improvement in 68-tender and 66-swollen joint counts and 50% improvement in at least 3 of the 5 measures: patient's global assessment of arthritis, physician global assessment of arthritis, patient's assessment of arthritis pain, health assessment questionnaire-disability index(HAQ-DI) and CRP. Patient's global assessment of arthritis: participant assessed arthritis by 100 mm VAS, score: 0 mm (no arthritis) to 100 mm (extreme arthritis), higher score implied more arthritis. Physician global assessment of arthritis: physician judged participants arthritis by 100 mm VAS, score: 0 mm (no arthritis) to 100 mm (extreme arthritis), higher score implied more arthritis. Patient's assessment of arthritis pain: participant assessed arthritis pain by 100 mm VAS, score: 0 mm (no pain) to 100 mm (most severe pain), higher score implied more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.

    Time frame: Week 12

  4. Number of Participants Achieving an American College of Rheumatology 70% (ACR70) Response at Week 12

    Participants with 70% improvement in 68-tender and 66-swollen joint counts and 70% improvement in at least 3 of the 5 measures: patient's global assessment of arthritis, physician global assessment of arthritis, patient's assessment of arthritis pain, health assessment questionnaire-disability index(HAQ-DI) and CRP. Patient's global assessment of arthritis: participant assessed arthritis by 100 mm VAS, score: 0 mm (no arthritis) to 100 mm (extreme arthritis), higher score implied more arthritis. Physician global assessment of arthritis: physician judged participants arthritis by 100 mm VAS, score: 0 mm (no arthritis) to 100 mm (extreme arthritis), higher score implied more arthritis. Patient's assessment of arthritis pain: participant assessed arthritis pain by 100 mm VAS, score: 0 mm (no pain) to 100 mm (most severe pain), higher score implied more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.

    Time frame: Week 12

  5. Number of Participants With DAS Remission (DAS28-4-CRP <2.6) at Week 12

    DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP) was calculated from SJC and TJC using 28 joints count, CRP (mg/L) and patient global assessment of disease activity on a 100 mm visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (CRP) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (CRP) \<=3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (CRP) \<2.6 implied remission. Number of participants with DAS remission (DAS28-4-CRP\<2.6) were reported in this outcome measure.

    Time frame: Week 12

  6. Number of Participants With DAS Remission (DAS28-4-ESR <2.6) at Week 12

    DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hr) and patient global assessment of disease activity on a 100 mm visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (ESR) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (ESR) \<= 3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (ESR) \<2.6 implied remission. Number of participants with DAS remission (DAS28-4-ESR\<2.6) were reported in this outcome measure.

    Time frame: Week 12

  7. Number of Participants With Low Disease Activity (DAS28-4-CRP <=3.2) at Week 12

    DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP) was calculated from SJC and TJC using 28 joints count, CRP (mg/L) and patient global assessment of disease activity on a 100 mm visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (CRP) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (CRP) \<=3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (CRP) \<2.6 implied remission. Number of participants with low disease activity (DAS28-4-CRP\<=3.2) were reported in this outcome measure.

    Time frame: Week 12

  8. Number of Participants With Low Disease Activity (DAS28-4-ESR <=3.2) at Week 12

    DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hr) and patient global assessment of disease activity on a 100 mm visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (ESR) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (ESR) \<=3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (ESR) \<2.6 implied remission. Number of participants with low disease activity (DAS28-4-ESR\<=3.2) were reported in this outcome measure.

    Time frame: Week 12

  9. Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12

    HAQ-DI assesses the degree of difficulty a participant has experienced during the past week in 8 categories of daily living activities: dressing/grooming; arising; eating; walking; reach; grip; hygiene; and other activities over past week. Each activity category consisted of 2-3 items. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty) and 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities.

    Time frame: Baseline, Week 12

  10. Number of Participants Achieving an Improvement of at Least 0.22 Units in Health Assessment Questionnaire (HAQ Scores) at Week 12

    HAQ-DI assesses the degree of difficulty a participant has experienced during the past week in 8 categories of daily living activities: dressing/grooming; arising; eating; walking; reach; grip; hygiene; and other activities over past week. Each activity category consisted of 2-3 items. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty) and 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities. Number of participants with an improvement of at least 0.22 units in HAQ scores from baseline to Week 12 were reported in this outcome measure.

    Time frame: Week 12

  11. Change From Baseline in the Short Form 36 (SF-36) Health Survey Domain Scores at Week 12

    SF-36 is a participant reported standardized survey designed to assess generic health related quality of life. It consisted of 36 items evaluating 8 aspects of functional health and well-being: physical functioning, role physical, bodily pain, social functioning, mental health, role emotional, vitality, and general health. The score range for each of the 8 health aspects was from 0 (poor health) to 100 (better health), higher scores indicating good health condition. Scores of 8 health aspects were aggregated to derive the two component scores (physical component scores \[PCS\], mental component scores \[MCS\]) ranging from 0 (worst) to 100 (best), where higher scores indicated good health condition.

    Time frame: Baseline, Week 12

  12. Change From Baseline in the Short Form 36 (SF-36) Health Survey Component Scores at Week 12

    SF-36 is a participant reported standardized survey designed to assess generic health related quality of life. It consisted of 36 items evaluating 8 aspects of functional health and well-being: physical functioning, role physical, bodily pain, social functioning, mental health, role emotional, vitality, and general health. The score range for each of the 8 health aspects was from 0 (poor health) to 100 (better health), higher scores indicating good health condition. Scores of 8 health aspects were aggregated to derive the two component scores PCS and MCS ranging from 0 (worst) to 100 (best), where higher scores indicated good health condition.

    Time frame: Baseline, Week 12

  13. Change From Baseline in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Scores at Week 12

    The FACIT-Fatigue Scale was a participant completed questionnaire consisted of 13 items that assessed fatigue. Each item was scored on a scale of 0 (not at all) to 4 (very much), Total score ranging from 0 (not at all) to 52 (very much), higher scores represented lower level of fatigue.

    Time frame: Baseline, Week 12

  14. Change From Baseline in the European Quality of Life - 5 Dimensions Questionnaire (EQ-5D) Scores at Week 12

    EQ-5D was a participant completed instrument designed to assess impact on quality of life in terms of a single utility score in five domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression with 3 possible answers for each item (1=no problem, 2=moderate problems, 3=severe problems). The 5-dimensional systems are converted into a single index utility score between 0 and 1, where higher score indicated a better health state.

    Time frame: Baseline, Week 12

Other outcomes

  1. Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An Adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events between first dose of study drug and up to 12 weeks that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non- serious adverse events.

    Time frame: Baseline up to 12 weeks

  2. Number of Participants With Clinically Significant Laboratory Test Abnormalities

    Criteria: lipids(cholesterol\[CH\] milligrams/deciliter\[mg/dL\] \>1.3\*upper limit normal(ULN), high-density lipoprotein CH mg/dL \<0.8\*lower limit normal(LLN), Low-density lipoprotein CH mg/dL \>1.2\* ULN, triglycerides mg/dL \>1.3\*ULN); neutrophil count(NC) \<1000 cells/cubic milliliters(mm\^3), platelet counts(PC) \<100,000 P/mm\^3, lymphocyte counts(LC) \<500 L/mm\^3, any single (aspartate transaminase elevation(ASTE)/alanine transaminase elevation(ALTE) \>=3\*ULN, hemoglobin(Hb) value \<8.0 grams(g)/dL or \>=2 g/dL below baseline, any serum creatinine(SC) increase(inc) \>50% or inc \>0.5 mg/dL over the average of screening(OAS) and baseline values(BV), 2 sequential ASTE/ALTE\>=3\*ULN with total bilirubin value(TBV) \>=2\*ULN, ASTE/ALTE \>=3\*ULN, ASTE/ALTE \>=5\*ULN, Hb \<8.0 g/dL or decrease of \>30% from BV, PC \<75,000 P/mm\^3, NC \<1000 cells/mm\^3, LC \<500 L/mm\^3, confirmed inc in SC \>50% OAS and BV and detection of hepatitis B virus-deoxyribonucleic acid(HBV-DNA) by the two sequential quantitative tests.

    Time frame: Baseline up to 12 weeks

07

Results

Posted Oct 12, 2018

Participant flow

Participant flow — Overall Study
MilestoneTofacitinib Modified Release (MR)Tofacitinib Immediate Release (IR)
Started104105
Completed10095
Not completed410
Withdrew: Medication error10
Withdrew: Insufficient clinical response01
Withdrew: Adverse event39

Outcome measures

PrimaryChange From Baseline in Disease Activity Score in 28 Joints Using 4 Variables (DAS28-4) (C-Reactive Protein [CRP]) at Week 12

DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP) was calculated from swollen joint count (SJC) and tender/painful joint count (TJC) using 28 joints count, CRP (milligrams per liter \[mg/L\]) and patient global assessment of disease activity on a 100 millimeter (mm) visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (CRP) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (CRP) \[less than or equal to\] \<= 3.2 implied low disease activity and greater than (\>) 3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (CRP) less than (\<) 2.6 implied remission.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Disease Activity Score in 28 Joints Using 4 Variables (DAS28-4) (C-Reactive Protein [CRP]) at Week 12
units on a scaleTofacitinib Modified Release (MR)Tofacitinib Immediate Release (IR)
Change From Baseline in Disease Activity Score in 28 Joints Using 4 Variables (DAS28-4) (C-Reactive Protein [CRP]) at Week 12-2.43 ± 0.09-2.85 ± 0.09
Statistical analysis
  • Tofacitinib Modified Release (MR) vs Tofacitinib Immediate Release (IR) · Least square (ls) mean difference: 0.43 · 95% CI 0.17 to 0.69
SecondaryChange From Baseline in Disease Activity Score in 28 Joints Using 4 Variables (DAS28-4) (Erythrocyte Sedimentation Rate [ESR]) at Week 12

DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (millimeters per hour \[mm/hr\]) and patient global assessment of disease activity on a 100 mm visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (ESR) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (ESR) \<=3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (ESR) \<2.6 implied remission.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Disease Activity Score in 28 Joints Using 4 Variables (DAS28-4) (Erythrocyte Sedimentation Rate [ESR]) at Week 12
units on a scaleTofacitinib Modified Release (MR)Tofacitinib Immediate Release (IR)
Change From Baseline in Disease Activity Score in 28 Joints Using 4 Variables (DAS28-4) (Erythrocyte Sedimentation Rate [ESR]) at Week 12-2.50 ± 0.09-2.86 ± 0.09
SecondaryNumber of Participants Achieving an American College of Rheumatology 20 Percent [%] (ACR20) Response at Week 12

Participants with 20% improvement in 68-tender and 66-swollen joint counts and 20% improvement in at least 3 of the 5 measures: patient's global assessment of arthritis, physician global assessment of arthritis, patient's assessment of arthritis pain, health assessment questionnaire-disability index(HAQ-DI) and CRP. Patient's global assessment of arthritis: participant assessed arthritis by 100 mm VAS, score: 0 mm (no arthritis) to 100 mm (extreme arthritis), higher score implied more arthritis. Physician global assessment of arthritis: physician judged participants arthritis by 100 mm VAS, score: 0 mm (no arthritis) to 100 mm (extreme arthritis), higher score implied more arthritis. Patient's assessment of arthritis pain: participant assessed arthritis pain by 100 mm VAS, score: 0 mm (no pain) to 100 mm (most severe pain), higher score implied more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.

Time frame:
Week 12
Reported as:
Number · participants
Number of Participants Achieving an American College of Rheumatology 20 Percent [%] (ACR20) Response at Week 12
participantsTofacitinib Modified Release (MR)Tofacitinib Immediate Release (IR)
Number of Participants Achieving an American College of Rheumatology 20 Percent [%] (ACR20) Response at Week 128783
SecondaryNumber of Participants Achieving an American College of Rheumatology 50% (ACR50) Response at Week 12

Participants with 50% improvement in 68-tender and 66-swollen joint counts and 50% improvement in at least 3 of the 5 measures: patient's global assessment of arthritis, physician global assessment of arthritis, patient's assessment of arthritis pain, health assessment questionnaire-disability index(HAQ-DI) and CRP. Patient's global assessment of arthritis: participant assessed arthritis by 100 mm VAS, score: 0 mm (no arthritis) to 100 mm (extreme arthritis), higher score implied more arthritis. Physician global assessment of arthritis: physician judged participants arthritis by 100 mm VAS, score: 0 mm (no arthritis) to 100 mm (extreme arthritis), higher score implied more arthritis. Patient's assessment of arthritis pain: participant assessed arthritis pain by 100 mm VAS, score: 0 mm (no pain) to 100 mm (most severe pain), higher score implied more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.

Time frame:
Week 12
Reported as:
Number · participants
Number of Participants Achieving an American College of Rheumatology 50% (ACR50) Response at Week 12
participantsTofacitinib Modified Release (MR)Tofacitinib Immediate Release (IR)
Number of Participants Achieving an American College of Rheumatology 50% (ACR50) Response at Week 127071
SecondaryNumber of Participants Achieving an American College of Rheumatology 70% (ACR70) Response at Week 12

Participants with 70% improvement in 68-tender and 66-swollen joint counts and 70% improvement in at least 3 of the 5 measures: patient's global assessment of arthritis, physician global assessment of arthritis, patient's assessment of arthritis pain, health assessment questionnaire-disability index(HAQ-DI) and CRP. Patient's global assessment of arthritis: participant assessed arthritis by 100 mm VAS, score: 0 mm (no arthritis) to 100 mm (extreme arthritis), higher score implied more arthritis. Physician global assessment of arthritis: physician judged participants arthritis by 100 mm VAS, score: 0 mm (no arthritis) to 100 mm (extreme arthritis), higher score implied more arthritis. Patient's assessment of arthritis pain: participant assessed arthritis pain by 100 mm VAS, score: 0 mm (no pain) to 100 mm (most severe pain), higher score implied more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.

Time frame:
Week 12
Reported as:
Number · participants
Number of Participants Achieving an American College of Rheumatology 70% (ACR70) Response at Week 12
participantsTofacitinib Modified Release (MR)Tofacitinib Immediate Release (IR)
Number of Participants Achieving an American College of Rheumatology 70% (ACR70) Response at Week 123248
SecondaryNumber of Participants With DAS Remission (DAS28-4-CRP <2.6) at Week 12

DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP) was calculated from SJC and TJC using 28 joints count, CRP (mg/L) and patient global assessment of disease activity on a 100 mm visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (CRP) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (CRP) \<=3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (CRP) \<2.6 implied remission. Number of participants with DAS remission (DAS28-4-CRP\<2.6) were reported in this outcome measure.

Time frame:
Week 12
Reported as:
Number · participants
Number of Participants With DAS Remission (DAS28-4-CRP <2.6) at Week 12
participantsTofacitinib Modified Release (MR)Tofacitinib Immediate Release (IR)
Number of Participants With DAS Remission (DAS28-4-CRP <2.6) at Week 125272
SecondaryNumber of Participants With DAS Remission (DAS28-4-ESR <2.6) at Week 12

DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hr) and patient global assessment of disease activity on a 100 mm visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (ESR) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (ESR) \<= 3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (ESR) \<2.6 implied remission. Number of participants with DAS remission (DAS28-4-ESR\<2.6) were reported in this outcome measure.

Time frame:
Week 12
Reported as:
Number · participants
Number of Participants With DAS Remission (DAS28-4-ESR <2.6) at Week 12
participantsTofacitinib Modified Release (MR)Tofacitinib Immediate Release (IR)
Number of Participants With DAS Remission (DAS28-4-ESR <2.6) at Week 121836
SecondaryNumber of Participants With Low Disease Activity (DAS28-4-CRP <=3.2) at Week 12

DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP) was calculated from SJC and TJC using 28 joints count, CRP (mg/L) and patient global assessment of disease activity on a 100 mm visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (CRP) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (CRP) \<=3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (CRP) \<2.6 implied remission. Number of participants with low disease activity (DAS28-4-CRP\<=3.2) were reported in this outcome measure.

Time frame:
Week 12
Reported as:
Number · participants
Number of Participants With Low Disease Activity (DAS28-4-CRP <=3.2) at Week 12
participantsTofacitinib Modified Release (MR)Tofacitinib Immediate Release (IR)
Number of Participants With Low Disease Activity (DAS28-4-CRP <=3.2) at Week 127682
SecondaryNumber of Participants With Low Disease Activity (DAS28-4-ESR <=3.2) at Week 12

DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hr) and patient global assessment of disease activity on a 100 mm visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (ESR) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (ESR) \<=3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (ESR) \<2.6 implied remission. Number of participants with low disease activity (DAS28-4-ESR\<=3.2) were reported in this outcome measure.

Time frame:
Week 12
Reported as:
Number · participants
Number of Participants With Low Disease Activity (DAS28-4-ESR <=3.2) at Week 12
participantsTofacitinib Modified Release (MR)Tofacitinib Immediate Release (IR)
Number of Participants With Low Disease Activity (DAS28-4-ESR <=3.2) at Week 124463
SecondaryChange From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12

HAQ-DI assesses the degree of difficulty a participant has experienced during the past week in 8 categories of daily living activities: dressing/grooming; arising; eating; walking; reach; grip; hygiene; and other activities over past week. Each activity category consisted of 2-3 items. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty) and 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12
units on a scaleTofacitinib Modified Release (MR)Tofacitinib Immediate Release (IR)
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12-0.44 ± 0.04-0.46 ± 0.04
SecondaryNumber of Participants Achieving an Improvement of at Least 0.22 Units in Health Assessment Questionnaire (HAQ Scores) at Week 12

HAQ-DI assesses the degree of difficulty a participant has experienced during the past week in 8 categories of daily living activities: dressing/grooming; arising; eating; walking; reach; grip; hygiene; and other activities over past week. Each activity category consisted of 2-3 items. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty) and 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities. Number of participants with an improvement of at least 0.22 units in HAQ scores from baseline to Week 12 were reported in this outcome measure.

Time frame:
Week 12
Reported as:
Number · participants
Number of Participants Achieving an Improvement of at Least 0.22 Units in Health Assessment Questionnaire (HAQ Scores) at Week 12
participantsTofacitinib Modified Release (MR)Tofacitinib Immediate Release (IR)
Number of Participants Achieving an Improvement of at Least 0.22 Units in Health Assessment Questionnaire (HAQ Scores) at Week 126560
SecondaryChange From Baseline in the Short Form 36 (SF-36) Health Survey Domain Scores at Week 12

SF-36 is a participant reported standardized survey designed to assess generic health related quality of life. It consisted of 36 items evaluating 8 aspects of functional health and well-being: physical functioning, role physical, bodily pain, social functioning, mental health, role emotional, vitality, and general health. The score range for each of the 8 health aspects was from 0 (poor health) to 100 (better health), higher scores indicating good health condition. Scores of 8 health aspects were aggregated to derive the two component scores (physical component scores \[PCS\], mental component scores \[MCS\]) ranging from 0 (worst) to 100 (best), where higher scores indicated good health condition.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Short Form 36 (SF-36) Health Survey Domain Scores at Week 12
units on a scaleTofacitinib Modified Release (MR)Tofacitinib Immediate Release (IR)
Physical Functioning5.54 ± 0.676.29 ± 0.68
Role Physical6.51 ± 0.816.97 ± 0.83
Bodily Pain9.41 ± 0.7711.92 ± 0.78
General Health4.53 ± 0.524.72 ± 0.53
Vitality8.07 ± 0.758.20 ± 0.76
Social Function4.26 ± 0.635.06 ± 0.64
Role Emotional7.23 ± 0.866.56 ± 0.87
Mental Health4.46 ± 0.805.26 ± 0.81
SecondaryChange From Baseline in the Short Form 36 (SF-36) Health Survey Component Scores at Week 12

SF-36 is a participant reported standardized survey designed to assess generic health related quality of life. It consisted of 36 items evaluating 8 aspects of functional health and well-being: physical functioning, role physical, bodily pain, social functioning, mental health, role emotional, vitality, and general health. The score range for each of the 8 health aspects was from 0 (poor health) to 100 (better health), higher scores indicating good health condition. Scores of 8 health aspects were aggregated to derive the two component scores PCS and MCS ranging from 0 (worst) to 100 (best), where higher scores indicated good health condition.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Short Form 36 (SF-36) Health Survey Component Scores at Week 12
units on a scaleTofacitinib Modified Release (MR)Tofacitinib Immediate Release (IR)
PCS6.59 ± 0.587.85 ± 0.59
MCS5.29 ± 0.765.08 ± 0.77
SecondaryChange From Baseline in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Scores at Week 12

The FACIT-Fatigue Scale was a participant completed questionnaire consisted of 13 items that assessed fatigue. Each item was scored on a scale of 0 (not at all) to 4 (very much), Total score ranging from 0 (not at all) to 52 (very much), higher scores represented lower level of fatigue.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Scores at Week 12
units on a scaleTofacitinib Modified Release (MR)Tofacitinib Immediate Release (IR)
Change From Baseline in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Scores at Week 125.28 ± 0.666.12 ± 0.67
SecondaryChange From Baseline in the European Quality of Life - 5 Dimensions Questionnaire (EQ-5D) Scores at Week 12

EQ-5D was a participant completed instrument designed to assess impact on quality of life in terms of a single utility score in five domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression with 3 possible answers for each item (1=no problem, 2=moderate problems, 3=severe problems). The 5-dimensional systems are converted into a single index utility score between 0 and 1, where higher score indicated a better health state.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in the European Quality of Life - 5 Dimensions Questionnaire (EQ-5D) Scores at Week 12
units on a scaleTofacitinib Modified Release (MR)Tofacitinib Immediate Release (IR)
Change From Baseline in the European Quality of Life - 5 Dimensions Questionnaire (EQ-5D) Scores at Week 120.20 ± 0.020.25 ± 0.02
Other pre-specifiedNumber of Participants With Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An Adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events between first dose of study drug and up to 12 weeks that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non- serious adverse events.

Time frame:
Baseline up to 12 weeks
Reported as:
Number · participants
Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
participantsTofacitinib Modified Release (MR)Tofacitinib Immediate Release (IR)
AEs5554
SAEs54
Other pre-specifiedNumber of Participants With Clinically Significant Laboratory Test Abnormalities

Criteria: lipids(cholesterol\[CH\] milligrams/deciliter\[mg/dL\] \>1.3\*upper limit normal(ULN), high-density lipoprotein CH mg/dL \<0.8\*lower limit normal(LLN), Low-density lipoprotein CH mg/dL \>1.2\* ULN, triglycerides mg/dL \>1.3\*ULN); neutrophil count(NC) \<1000 cells/cubic milliliters(mm\^3), platelet counts(PC) \<100,000 P/mm\^3, lymphocyte counts(LC) \<500 L/mm\^3, any single (aspartate transaminase elevation(ASTE)/alanine transaminase elevation(ALTE) \>=3\*ULN, hemoglobin(Hb) value \<8.0 grams(g)/dL or \>=2 g/dL below baseline, any serum creatinine(SC) increase(inc) \>50% or inc \>0.5 mg/dL over the average of screening(OAS) and baseline values(BV), 2 sequential ASTE/ALTE\>=3\*ULN with total bilirubin value(TBV) \>=2\*ULN, ASTE/ALTE \>=3\*ULN, ASTE/ALTE \>=5\*ULN, Hb \<8.0 g/dL or decrease of \>30% from BV, PC \<75,000 P/mm\^3, NC \<1000 cells/mm\^3, LC \<500 L/mm\^3, confirmed inc in SC \>50% OAS and BV and detection of hepatitis B virus-deoxyribonucleic acid(HBV-DNA) by the two sequential quantitative tests.

Time frame:
Baseline up to 12 weeks
Reported as:
Number · participants
Number of Participants With Clinically Significant Laboratory Test Abnormalities
participantsTofacitinib Modified Release (MR)Tofacitinib Immediate Release (IR)
Cholesterol118
High-density lipoprotein Cholesterol11
Low-density lipoprotein Cholesterol2221
Triglycerides610
Neutrophil counts <1000 cells/mm300
Platelet counts <100,000 platelets/mm300
Lymphocyte counts <500 lymphocytes/mm310
Any single AST and/or ALT elevation >=3xULN10
Any single Hb value <8.0 g/dL or >=2 gm/dL02
Any serum creatinine increase >50%00
2sequential AST/ALT elevations>=3xULN, TBV>=2xULN00
2 sequential AST or ALT elevations >=3xULN10
2 sequential AST or ALT elevations >=5xULN00
2sequential Hb<8.0 g/dL or decrease of >30%from BV01
2 sequential platelet counts <75,000 platelets/mm300
2 sequential neutrophil counts <1000 cells/mm300
2 sequential lymphocyte count <500 lymphocytes/mm300
Confirmed increases in serum creatinine >50%00
Detection of HBV-DNA00

Adverse events

Collected over From baseline up to 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tofacitinib Modified Release (MR)0/104 (0%)5/104 (4.8%)10/104 (9.6%)
Tofacitinib Immediate Release (IR)0/105 (0%)4/105 (3.8%)13/105 (12.4%)
Most frequent serious events
Most frequent serious events
EventTofacitinib Modified Release (MR)Tofacitinib Immediate Release (IR)
Pneumocystis jirovecii pneumoniaInfections and infestations2/1041/105
PneumoniaInfections and infestations1/1041/105
Femoral neck fractureInjury, poisoning and procedural complications1/1040/105
Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1040/105
AnaemiaBlood and lymphatic system disorders0/1041/105
Pneumonia bacterialInfections and infestations0/1041/105
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders0/1041/105
Most frequent other events
Most frequent other events
EventTofacitinib Modified Release (MR)Tofacitinib Immediate Release (IR)
NasopharyngitisInfections and infestations10/10413/105

Baseline characteristics

Full analysis set (FAS) included all participants who were randomized and received at least one dose of the randomized investigational drug.

Age, Continuous
Age, Continuous(years)Tofacitinib Modified Release (MR)Tofacitinib Immediate Release (IR)Total
Mean57.1 ± 11.458.9 ± 10.258 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Tofacitinib Modified Release (MR)Tofacitinib Immediate Release (IR)Total
Female8675161
Male183048
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tofacitinib Modified Release (MR)Tofacitinib Immediate Release (IR)Total
Asian104105209
American Indian or Alaska Native000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

36 sites
  • Japanese Red Cross Nagoya Daiichi Hospital
    Nagoya, Aichi 453-8511, Japan
  • National Hospital Organization Nagoya Medical Center
    Nagoya, Aichi 460-0001, Japan
  • National Hospital Organization Toyohashi Medical Center
    Toyohashi, Aichi 440-8510, Japan
  • Yamada Rheumatology Clinic
    Matsuyama, Ehime 790-0905, Japan
  • St. Mary's Hospital
    Kurume, Fukuoka 830-8543, Japan
  • Gunma Rheumatism Clinic
    Takasaki-shi, Gunma 370-0004, Japan
  • Inoue Hospital
    Tohrimachi, Takasaki, Gunma 370-0053, Japan
  • Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
    Hiroshima-city, Hiroshima 730-8619, Japan
  • National Hospital Organization Asahikawa Medical Center
    Asahikawa, Hokkaido 070-8644, Japan
  • Katayama Orthopaedic Rheumatology Clinic
    Asahikawa, Hokkaido 078-8243, Japan
  • Yoshida orthopaedics and rheumatologyclinic
    Morioka, Iwate 020-0015, Japan
  • Komagamine Rheumatoid Orthopaedic Clinic
    Morioka, Iwate 020-0034, Japan
  • National Hospital Organization Sagamihara National Hospital
    Sagamihara, Kanagawa 252-0392, Japan
  • National Hospital Organization Yokohama Medical Center
    Yokohama, Kanagawa 245-8575, Japan
  • Osaki Citizen Hospital
    Oosaki, Miyagi 989-6183, Japan
  • Tohoku University Hospital/ Department of Hematology and Rheumatology
    Sendai, Miyagi 9808574, Japan
  • Nagano Red Cross Hospital
    Nagano-shi, Nagano 380-8582, Japan
  • Sasebo Chuo Hospital
    Sasebo, Nagasaki 857-1195, Japan
  • National Hospital Organization Ureshino Medical Center
    Ureshino-shi, Saga 843-0393, Japan
  • Soshigayaokura clinic
    Setagaya-ku, Tokyo 157-0073, Japan
  • Showa University Hospital
    Shinagawa-ku, Tokyo 142-8666, Japan
  • Honjo Rheumatism Clinic
    Takaoka-shi, Toyama 933-0874, Japan
  • Miyasato Clinic
    Shunan, Yamaguchi 745-0824, Japan
  • National Hospital Organization Chiba-East Hospital
    Chiba, 260-8712, Japan
  • Sugimoto rheumatology and internal medicine clinic
    Fukui, 910-0068, Japan
  • National Hospital Organization Kyushu Medical Center
    Fukuoka, 810-8563, Japan
  • SHONO Rheumatism Clinic
    Fukuoka, 814-0002, Japan
  • Sagawa Akira Rheumatology Clinic
    Hokkaido, 060-0001, Japan
  • Matsubara Mayflower Hospital
    Hyogo, 673-1462, Japan
  • Yokohama Minami Kyosai Hospital
    Kanagawa, 236-0037, Japan
  • Kumamoto Orthopaedic Hospital
    Kumamoto, 862-0976, Japan
  • Japanese Red Cross Kyoto Daiichi Hospital
    Kyoto, 605-0981, Japan
  • Oribe Clinic of Rheumatology and Internal Medicine
    Oita, 870-0823, Japan
  • Otsuka Clinic of Rheumatism and Medicine
    Oita, 870-1155, Japan
  • Rabbit Clinic
    Saitama, 336-0911, Japan
  • Hirose Clinic
    Saitama, 359-1111, Japan
09

References and documents

Publications

  • Tanaka Y, Sugiyama N, Toyoizumi S, Lukic T, Lamba M, Zhang R, Chen C, Stock T, Valdez H, Mojcik C, Fan H, Deng C, Yuasa H. Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study. Rheumatology (Oxford). 2019 Jan 1;58(1):70-79. doi: 10.1093/rheumatology/key250. PubMed 30137547 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Mar 2017, 27 months.

Results were first posted in Oct 2018, 1 year 6 months after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 27 months is above that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2014
First posted
Nov 2, 2014
StartActual
Nov 18, 2014
Primary completionActual
Mar 15, 2017
CompletionActual
Mar 15, 2017
Results first posted
Oct 12, 2018
Last update
Oct 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02281552
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 2, 2014
Start date
Nov 18, 2014
Primary completion
Mar 15, 2017
Completion
Mar 15, 2017
Results posted
Oct 12, 2018
Last update
Oct 12, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion